drugset

drugset / Trial / NCT07418229

Study to Evaluate the Safety of a Lyophilized RSV mRNA Vaccine

NCT07418229 ↗

Phase 1 Not yet recruiting 60 enrolled Sinovac Biotech Co., Ltd

RandomizedParallel-groupQuadruple-blindPrevention

Summary

To evaluate the safety of Sinovac RSV mRNA among participants aged ≥18 years

Timeline

Start: 2026-03-09
Primary completion: 2026-06-30
Completion: 2027-05-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	RSV mRNA vaccine	Messenger RNA (mRNA)	—	—

Indications